The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health DOI Creative Commons

Mohamad Al Qassab,

M.A. Mneimneh,

Ahmad Jradi

и другие.

Current Issues in Molecular Biology, Год журнала: 2025, Номер 47(4), С. 285 - 285

Опубликована: Апрель 17, 2025

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as a promising therapeutic option beyond their established role in managing type 2 diabetes mellitus (T2DM) and obesity. Recent research has highlighted beneficial effects on liver, kidney, cardiovascular health, mediated by both direct indirect mechanisms. In the GLP-1 RAs contribute to improvement of metabolic dysfunction-associated steatotic liver disease (MASLD) reducing hepatic fat accumulation, inflammation, oxidative stress. Additionally, they enhance insulin sensitivity lipid metabolism. Similarly, diabetic kidney (DKD), exhibit renoprotective properties mitigating stress, glomerular hypertension. Furthermore, promote natriuresis stabilize renal function. Moreover, present significant benefits, including improved myocardial function, reduced atherosclerosis progression, enhanced endothelial decreased major adverse events (MACEs). emerging evidence suggests may exert substantial neuropsychiatric reductions depressive symptoms, anxiety, substance use behaviors, lowering risk Alzheimer’s disease, Parkinson’s other dementias likely modulation neurotransmitter systems neuroinflammation. Genetic polymorphisms GLP1R gene also impact response, highlighting importance personalized medicine optimizing RA efficacy. This review synthesizes preclinical clinical supporting multifaceted across multiple organ systems, potential glycemic control. As advances, further exploration mechanisms action long-term outcomes, safety effectiveness diverse patient populations will be essential treating conditions.

Язык: Английский

The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health DOI Creative Commons

Mohamad Al Qassab,

M.A. Mneimneh,

Ahmad Jradi

и другие.

Current Issues in Molecular Biology, Год журнала: 2025, Номер 47(4), С. 285 - 285

Опубликована: Апрель 17, 2025

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as a promising therapeutic option beyond their established role in managing type 2 diabetes mellitus (T2DM) and obesity. Recent research has highlighted beneficial effects on liver, kidney, cardiovascular health, mediated by both direct indirect mechanisms. In the GLP-1 RAs contribute to improvement of metabolic dysfunction-associated steatotic liver disease (MASLD) reducing hepatic fat accumulation, inflammation, oxidative stress. Additionally, they enhance insulin sensitivity lipid metabolism. Similarly, diabetic kidney (DKD), exhibit renoprotective properties mitigating stress, glomerular hypertension. Furthermore, promote natriuresis stabilize renal function. Moreover, present significant benefits, including improved myocardial function, reduced atherosclerosis progression, enhanced endothelial decreased major adverse events (MACEs). emerging evidence suggests may exert substantial neuropsychiatric reductions depressive symptoms, anxiety, substance use behaviors, lowering risk Alzheimer’s disease, Parkinson’s other dementias likely modulation neurotransmitter systems neuroinflammation. Genetic polymorphisms GLP1R gene also impact response, highlighting importance personalized medicine optimizing RA efficacy. This review synthesizes preclinical clinical supporting multifaceted across multiple organ systems, potential glycemic control. As advances, further exploration mechanisms action long-term outcomes, safety effectiveness diverse patient populations will be essential treating conditions.

Язык: Английский

Процитировано

0